Company Brochure - Galderma

Committed
to the future
of dermatology

Vibrant.
Visionary.
A dermatology company
like no other.
2
Innovative medical solutions that meet
the needs of dermatology patients and
physicians.
Premier investor in dermatology research
State-of-the-art global research and development
Focus on therapeutic, corrective and aesthetic
innovations

Dermatology
expertise
Galderma is a global pharmaceutical
company specializing in the research,
development and marketing of innovative
medical solutions for dermatology patients.
Created in 1981, the company today has
operations in thirty-one countries and a
worldwide network of exclusive sales agents.
Committed to the future of dermatology,
Galderma’s ambition is to be recognized
as the most competent and successful
innovation-based company focused exclusi-
vely on meeting the needs of dermatology
patients and physicians.

Company
milestones
1961
Founding of Owen Laboratories,
a dermatology company in Dallas,
Texas, USA.
1972
Acquisition of Owen by
ophthalmology specialist Alcon,
Fort Worth, Texas.
1977
Nestlé acquires Alcon to strengthen
its presence in the United States.
1979
L’Oréal opens its International
Dermatology Research Center
(CIRD) in Sophia-Antipolis, France,
specializing in fundamental
research in skin physiology.
Creation of Galderma Pharma,
Switzerland.
1981
Nestlé and L’Oréal form a joint venture:
Galderma is born.
1986
Galderma’s first operations open
for business in France, Italy and
Switzerland.
1989
New affiliates established in
Canada, United States, Germany,
Spain and the United Kingdom.
A global organization starts to take
shape.
1993
Acquisition of MetroGel ® /Rozex ®
(rosacea treatment).
1994
Galderma inaugurates its first
production plant in Alby-sur-Chéran,
France.
1995
Galderma launches its first
homegrown dermatology product:
Differin® (topical retinoid for acne
treatment).
1997
Acquisition of Basotherm, part of
the German group Boehringer.
1999
Inauguration of new R&D facility
in Princeton, New Jersey, USA.
Acquisition of Loceryl ® (a topical
anti-fungal agent for treating
onychomycosis).
.2000
Galderma’s second production unit
comes on line in Baie d'Urfé, Canada.
Launch of Silkis ® (psoriasis) and
acquisition of Capex ® Shampoo
(a high-potency corticosteroid for
seborrheic dermatitis).
2001
Licensing agreement obtained
for Metvix ® (non melanoma skin
cancer). Launch of Clindagel ®
(a topical antibiotic for treating acne).
2002
Licensing agreements obtained
for Tri-Luma ® (topical treatment for
melasma) worldwide and Pekiron ®
(Loceryl ® Cream) in Japan.
2003
Launch of Metvix ® (skin cancer) and
Clobex ® Lotion (high-potency topical
corticosteroid for psoriasis).
2004
New production site opened
in Hortolandia, Brazil. Launch of
Clobex ® Shampoo. Galderma
acquires Tri-Luma ® (melasma).
2005
Galderma ranks number one in
dermatology (D class) in its markets.
Launch of Metrogel ® 1% (rosacea).
2006
Launch of Clobex ® Spray (psoriasis).
Opening of Galderma’s
new state-of-the-art R&D center
in Sophia-Antipolis, France.
2007
Licensing agreements for Pli aglis ®
(topical anaesthetic) and a
botulinum toxin Type A. Launch of
Differin ® 0.3% (acne).
2008
Launch of Epiduo ® (acne).
Acquisition of CollaGenex and its
product Oracea ® (rosacea). Launch
of Differin ® 0.1% Gel in Japan.
2009
Launch of Vectical (psoriasis),
Oracea ® (rosacea) and Azzalure ®
(glabellar lines).
2010
Launch of Differin ® Lotion 0.1%.

“Just as the skin is a unique system within the human
body, caring for the skin requires specialized knowledge
and unique skills. At Galderma, we are focused
exclusively on advancing the science of skin. By providing
physicians around the world with a full range of
innovative products and services. By aggressively
researching leading-edge therapies. And by never
forgetting that the best way to care for skin is to care
for people, too.”
Close to patients
worldwide
Galderma is one of the leading key players in the worldwide
dermatology market. Its name is associated with over
a dozen major products in some seventy countries.
Galderma generates over half of its revenues in North
America and a quarter in Europe. Sales in Latin America,
Asia, the Middle East, Australia and Africa are steadily
growing.
To meet evolving patient needs,
Galderma focuses on:
Developing innovative medical solutions for the diagnosis,
prevention and treatment of dermatological diseases;
R&D investment in targeted areas: acne, rosacea,
psoriasis/steroid-responsive dermatoses, onychomycosis,
pigmentary disorders, skin cancer and medical
solutions for skin senescence;
Fostering partnerships with dermatologists and the
international scientific community.
3

Enhancing
skin health
Galderma’s R&D investments, expertise and partnerships (scientific collaborations,
acquisitions and licensing) are geared toward finding medical solutions for a number
of important skin conditions.
Acne
Acne is a chronic skin disease involving inflammation of the
sebaceous glands that affects 80% of teenagers and many
adults over the age of thirty, especially females. It occurs
when there are changes in hormone levels and abnormal
keratinization, which can cause plugging (comedons) and
inflamed lesions (red pimples). Acne most commonly
appears on the face but can also occur on the back and
the chest.
Skin cancer
Actinic keratosis (AK) is the most common warning signal of skin cancer in persons
with fair complexion. The lesions appear as rough, scaly patches on sun-exposed
areas of the body, such as on the face, bald scalp or the back of the hands. If left
untreated, they can develop into a form of skin cancer called squamous cell carcinoma.
Basal cell carcinoma (BCC) is the most common skin cancer among fair-skinned
individuals. It affects mainly sun-exposed areas of the skin. BCCs are not life-threatening
but enlarge slowly, are locally invasive and can ulcerate. They will not regress spontaneously.
Bowen’s disease is a squamous cell carcinoma of the superficial layer of the skin. The
face, hands, genital region, trunk and lower legs are commonly affected. The lesions
present as single, flat, slightly raised patches of red, occasionally pigmented, scaly
skin and develop very slowly. If left untreated, the lesion can become invasive.
Onychomycosis
Onychomycosis (or nail mycosis) is an
increasingly common disorder, affecting some
10 percent of the world’s population. One in
two people over the age of 70 suffer from it.
Onychomycosis is caused by a microscopic
fungus and tends to be more common in the
toe nails. It is a highly contagious disease that
can alter or even destroy the nail.
4

Psoriasis
Rosacea
Psoriasis vulgaris is a non-infectious, inflammatory
skin disorder characterized by red and sometimes
itchy patches. It affects about 2 to 3% of the world’s
population. It is a lifelong condition with relapses and
remissions that are both emotionally and physically
stressful. There is currently no cure. Treatment
consists in the management of signs and symptoms
with the aim of maximizing patient quality of life.
Rosacea is a chronic skin condition characterized by facial erytema and/or inflammatory
lesions. It most often affects people between the ages of 30 and 60 and tends
to occur more frequently among fair-skinned individuals with light-colored eyes. Ten
percent of North Europeans and North Americans suffer from this disorder.
Skin senescence
Caused by the passage of time but exacerbated following exposure to the sun and
UV rays (photo-aging) the visible signs of skin aging can be treated by corrective and
aesthetic dermatology. Medical products, such as botulinum toxin and dermal fillers,
or procedures, such as injections, laser therapies, etc., can be used to treat, correct
and improve the appearance of the skin.
Pigmentary disorders
More commonly known as the mask of pregnancy, melasma
is thought to affect 50 to 75% of pregnant women. This
hyperpigmentation disorder can occur following exposure to
the sun or hormonal changes (pregnancy, oral contraception,
etc.), causing an increase in melanin (the substance
that gives skin color). It is considered as a chronic disease
that can sometimes disappear a few months after giving birth,
reappear in subsequent pregnancies, or last for several years.
5

Expanding into
corrective
and aesthetic
dermatology
As the population in much of the world ages, an increasing number of people are
seeking to enrich the quality of their life by retaining a more youthful appearance.
This growing trend has become firmly established in many parts of the world and
is similarly becoming important to the growing middle class population in emerging
countries.
Corrective & aesthetic dermatology is the full range of medical solutions and
technologies used in the form of procedures or products. They are developed to
correct changes associated with or caused by clinical skin conditions or to restore
a younger skin appearance.
There are a number of different procedures and products that have been thus
developed in the corrective and aesthetic market to meet the needs of dermatology
patients and doctors.
Two of the more popular facial rejuvenation
procedures are treatments with
botulinum toxin, which is used to relax
facial muscles responsible for expression
lines (wrinkles and folds) in the
upper face, and treatments with dermal
fillers, which are traditionally used to fill
wrinkles and folds in the lips, cheeks and
chin or scars.
Since 2008, Galderma markets its botulinum
toxin type A, a local muscle
relaxant specifically designed for aesthetic
use. The company is also developing
a highly competitive portfolio of
hyaluronic acid-based products including
biopolymer technology.
6

Imaginative.
Innovative.
A dermatology company
like no other.
MetroGel ®

Dynamic.
Determined.
A dermatology company
like no other.

Metvix
Loceryl
Clobex
Rozex
Differin
Tri-Luma
Oracea
MetroGel
Cetaphil
7
Tetralysal
Silkis/Vectical
Azzalure
Epiduo

The world’s largest
R&D center
dedicated to dermatology
8
Sophia-Antipolis, France
Sophia-Antipolis, investing
in forward-looking R&D technology
Galderma’s main R&D center is located in southeast France, one of Europe’s foremost
science and technology hubs. A staff of nearly 450 work at the center which
hosts Galderma’s in-house research, pre-clinical and core development activities.
The 20.000-sq. meter state-of-the-art facility in Sophia-Antipolis, which was completed
in late 2006, has obtained dual ISO 14001 (environment) and OHSAS 18001
(safety) certification. This center positions Galderma as the world’s leading investor
in dermatology R&D and underpins its commitment to driving the future
of dermatology.

Dedicated R&D centers
for the American and Japanese markets
To closely address market needs, Galderma also conducts development in the United
States and Japan.
Located in New Jersey, USA, Galderma’s Princeton center specializes in clinical
development of products mainly for the North and Latin American markets.
The Tokyo facility focuses on clinical development and regulatory activities
specifically for the Japanese market.
Sophia-Antipolis, France
9
Key R&D
figures
3 R&D centers
21,8 %
of sales*
500 inventions
1700publications
510 employees
1750
product registrations
5 000 patent
applications and patents
* invested to discover and develop new drugs
and access innovative technologies

Promoting skin health
through partnerships
RISG
Rosacea International Study Group
In all four corners of the globe, Galderma helps scientists and healthcare professionals
deliver superior quality dermatology treatments. In doing so, Galderma enhances
the quality of life for millions of patients and helps advance the research that leads
to new therapies.
Galderma is actively engaged in programs and partnerships that provide data and
resources tailored to the needs of practitioners. For example, its DermQuest.com
website offers a vast pool of online clinical information available to practicing
dermatologists worldwide.
The company is a pivotal participant in the world’s leading international dermatology
congresses and conventions. World Congress of Dermatology (WCD), American
Academy of Dermatology (AAD), European Dermatology Forum (EDF), World
Congress on Cancers of the Skin (WCCS), European Congress on Psoriasis, European
Academy of Dermatology and Venereology (EADV), the principal U.S. dermatology
organizations, and more.
10
PIGMENTARY
DISORDERS
ACADEMY

Euroderm Excellence Meeting (Rome)
Galderma also fosters strong ties with the scientific community: Fondation René
Touraine, European Society for Dermatological Research (ESDR), Society for
Investigative Dermatology (SID), The Dermatology Foundation, Galderma Foundation,
and is involved in several university research programs in many countries. The
company has also developed close partnerships with biotech companies, other
pharmaceutical companies and numerous scientific service providers.
Galderma organizes and participates in innovative educational programs, such as
Euroderm Excellence and provides proactive support for advisory boards: International
Global Alliance to Improve Outcomes in Acne, Rosacea International Study Group,
Pigmentary Disorders Academy (PDA), Taskforce on Onychomycosis Education,
International Society for Photodynamic Therapy, and others…
AMWC Congress (Monaco)
11
AAD Congress (San Francisco)

Fostering
dermatology
excellence through a proactive
manufacturing strategy
Production site at Baie d'Urfé, Canada
Alby-sur-Chéran, France
With a workforce of 200, the company’s French site has an annual production capacity
of 30 million units. It manufactures the liquid and semi-liquid forms of products
on eight production lines and supplies over 70 countries in Europe, the Middle East,
Africa, Australia, Asia and South America. The site is ISO 14001 (environment) and
OHSAS 18001 (security) certified.
Galderma’s Industrial Development team of around 50 people is also based at
Alby-sur-Chéran. The unit develops clinical batches for trials worldwide. It also develops
and improves manufacturing processes for new products, acquisitions and
transfers, and supplies reference raw materials. Industrial Development is tasked with
leveraging Galderma’s technical prowess.
12
Production site at Alby-sur-Chéran, France
Galderma constantly strives to deliver
products offering the best quality, cost
and service benefits, all in strict
compliance with health, safety and environmental
protection standards. To
achieve these goals, the company’s
manufacturing capacity is spread across
three sites. Production site at Hortolandia, Brazil

Baie d'Urfé, Canada
Employing more than 220 people, Galderma’s Canadian site, ISO 14001 (environment),
OHSAS 18001 (security), FDA, ANVISA and Santé Canada certified, has seven
manufacturing platforms and eight production lines offering a combined annual
production capacity of 50 million units. Liquid and semi-liquid forms are manufactured
here: pharmaceutical products for the US and non-prescription products for all
the markets worldwide.
Hortolandia, Brazil
The Brazilian site employs around 40 people. Specializing in liquid and paste forms,
it offers an annual production capacity of 5 million units. Products manufactured in
Hortolandia are shipped throughout Brazil and other Latin American countries.
Baie d'Urfé plant, Canada
Key manufacturing
figures
3manufacturing sites
550 employees
85 million-unit annual production
capacity
860 product references
13
Alby-sur-Chéran plant, France

Talented people make the
difference
As a dermatology company, Galderma
operates in an exciting, complex
and demanding environment
where our people’s skills in a wide
range of disciplines such as Research
and Development, Manufacturing,
Quality, Logistics, Sales, Marketing,
Finance, Information Management…
can make all the difference.
We are committed to personal
development and encourage
our employees to nurture
and grow their skills through
on-the-job experience and
targeted training.
Individual performance, strong ethical
values and teamwork are key to
Galderma’s continued success.
We do not take success for granted and recognize that each individual has a part to
play in meeting our corporate objectives.
Advanced performance requires more than an unerring focus on results, products
and services or personal initiative. It also calls for a high level of personal engagement,
the ability to constantly improve organizations and business processes, as well as
effective relationships.
14

Key HR
figures
+3200
Workforce total
1350
Europe, Middle East-Africa,
Asia-Pacific, Latin America
620
North America
and more than
900
employees working closely
with physicians

Wealth of
diversity
Galderma is a company with a truly international dimension,
which values the contribution of each and every one of our
colleagues. Regardless of their backgrounds, everyone comes
together to pursue excellence and achieve our common goals.
Our employees enjoy a rich, professional environment and the
opportunity to contribute measurably to the company’s success.
Sharing knowledge
Knowledge transfer and ex -
change on a structured basis is
critical to business success. At
Galderma - because we believe
that efficient information flows
help speed up processes and
allow us to anticipate change -
we encourage our teams engaged
in different functions and
activities around the world to
work collaboratively.

A multi-cultural workplace
Galderma is not just an international company. It is a true
global player with the ambition to deploy a single vision and
strategy in all key markets.
Given our global ambitions, the diversity of our workforce
is a key asset.
Because our worldwide presence affords so many unique
international career prospects, mobility, an open mindset
and a taste for language and culture are qualities that are
highly valued at Galderma.
The opportunity to make
an impact through personal
engagement and initiative
As a young, innovative, international company, Galderma
offers a rare combination of advanced technology and high
global standards with room for personal initiative.
Excited.
Experienced.
A dermatology company
like no other.
15

A worldwide presence
Breakdown of worldwide sales
Latin
America
Europe/
Middle East/
Africa
11,1%
23,2%
7,7 %
16
58%
Asia/
Pacific
North
America

Galderma has 31 affiliates in the major countries of
the globe’s five continents. In more emerging economies, it is
represented by exclusive agents. Galderma products
are actively marketed in over 70 countries.
17

Adresses
Galderma sites worldwide
Parent Company
Galderma Pharma SA
Avenue Gratta-Paille 2
1018 Lausanne
SUISSE
Tel: + 41 21 642 78 00
Fax: + 41 21 642 78 01
Corporate Services
Galderma International SAS
Tour Europlaza - La Défense 4
20, avenue André Prothin
92927 La Défense Cedex
FRANCE
Tel: + 33 1 58 86 45 45
Fax: + 33 1 58 86 45 00
R&D Centers
FRANCE
Galderma R&D SNC
Les Templiers
2400, route des Colles
06410 Biot
Tel: + 33 4 93 95 70 70
Fax: + 33 4 93 95 70 71
JAPAN
Galderma KK (Japan)
9th Floor - Sumitomo Fudosan
Iidabashi
Nr. 3 Building
13-1 Nishi-Gokencho
Shinjyuku-ku
Tokyo 162-0812
Tel: + 81 3 5229 6930
Fax: + 81 3 5229 6957
UNITED STATES
Galderma R&D Inc.
5 Cedar Brook Drive - Suite 1
Cranbury, NJ 08512
Tel: + 1 609 409 7701
Fax: + 1 609 409 7705
Production sites
BRAZIL
Galderma Brasil Ltda.
Rodovia SP 101
Campinas - Monte Mor, Km9
Condominio Techtown
CEP 13186-904
Hortolandia - SP
Tel: + 55 11 3045 6900
Fax: + 55 19 3845 5261
CANADA
Galderma Production
Canada Inc.
19400 Trans-Canada Hwy
Baie d’Urfé - Québec
H9X 3S4
Tel: + 1 514 457 33 66
Fax: + 1 514 457 83 99
FRANCE
Laboratoires Galderma SAS
Zone Industrielle - Touvière
74540 Alby-sur-Chéran
Tel: + 33 4 50 68 31 33
Fax: + 33 4 50 68 33 00
Affiliates
ARGENTINA
Galderma Argentina SA
Juramento 1775 8º Piso
(C1428DNA)
Ciudad de Buenos Aires
Tel: + 54 11 4124 0454
Fax: + 54 11 4124 0211
info.argentina@galderma.com
www.galderma.com.ar
AUSTRALIA
Galderma Australia (Pty) Ltd.
Suite 4
13B Narabang Way
Belrose, N.S.W. 2085
Tel: + 61 2 9479 0600
Fax: + 61 2 9986 1699
info.au@galderma.com
BELGIUM
Galderma Belgilux NV
Fountain Business Center
Bornem
Gebouw 5 – Bus 205
Van Kerckhovenstraat 110
2880 Bornem
Tel: + 32 3 897 19 00
Fax: + 32 3 897 19 19
info.be@galderma.com
www.galderma.be
BRAZIL
Galderma Brasil Ltda.
Edifício E-Tower
Rua Funchal, 418 - 6° andar
Vila Olímpia - CEP 04551-060
Tel: + 55 11 3524 63 00
Fax: + 55 11 3524 63 29
sac@galderma.com
www.galderma.com.br
CANADA
Galderma Canada Inc.
105 Commerce Valley
Drive West - Suite 300
Thornhill - Ontario L3T 7W3
Tel: + 1 905 762 2500
Fax: + 1 905 762 2505
galdermacanada@galderma.com
www.galderma.ca
CHILE
Laboratorios Galderma Chile Ltda.
Mc Iver n° 440
Office n° 701
Santiago Centro
Tel: + 56 2 4807500
Fax: + 56 2 4807599
info.chile@galderma.com
www.galderma.cl
18
CHINA
Galderma International SAS
Beijing Representative Office
Unit 601 & 610 B, East
Ocean Centre
No. 24A Jianguomenwei Avenue
Beijing 100004
Tel: + 86 10 6515 7835/36
ext. 846
Fax: + 86 10 6515 7837
info.cn@galderma.com
COLOMBIA
Galderma de Colombia SA
Carrera 14, No. 93 B-32
Oficina 504
Bogotá, DC
Tel: + 57 1 622 7560 ext 201
Fax: + 57 1 622 76 05
info.colombia@galderma.com
www.galderma.com.co
FRANCE
Galderma International SAS
Tour Europlaza - La Défense 4
20, avenue André Prothin
92927 La Défense Cedex
Tel: + 33 1 58 86 45 45
Fax: + 33 1 58 86 45 00
info.france@galderma.com
www.galderma.fr
GERMANY
Galderma Laboratorium GmbH
Georg-Glock-Strasse 8
40474 Düsseldorf
Tel: + 49 211 58 601 04
Fax: + 49 211 45 440 08
germany@galderma.com
www.galderma.de
GREECE
Galderma Hellas Trade
of Pharmaceutical Products SA
Pendelis Avenue 37 A
15235 Vrilissia - Attica
Tel: + 30 210 81 04 190
Fax: + 30 210 81 04 194
galderma.hellas@galderma.com
HONG KONG
Galderma Hong Kong Ltd.
Room 1401,14/F
Phase 1, Ming An Plaza
8 Sunning Road – Causeway Bay
Tel: + 852 2824 0333
Fax: + 852 2827 7760
info.hkg@galderma.com
INDIA
Galderma India (Pvt.) Ltd.
23, Steelmade Industrial Estate
2nd Floor- Marol Village
Andheri (East)
Mumbai 400 059
Tel: + 91 22 6726 1818
Fax: + 91 22 6726 1807
galindia@galderma.com

Surprising.
Supportive.
A dermatology company
like no other.

Inspired.
Inventive.
A dermatology company
like no other.

ITALY
Galderma Italia S.p.A.
Centro Direzionale Colleoni
Palazzo Sirio - Ingresso 3
20041 Agrate B.ZA (MB)
Tel: + 39 (0)39 634 691
Fax: + 39 (0)39 60 91 830
info.italia@galderma.com
www.galderma.it
JAPAN
Galderma (Japan) KK
9th Floor - Sumitomo Fudosan
Iidabashi
Nr. 3 Building
13-1 Nishi-Gokencho
Shinjuku-ku
Tokyo 162-0812
Tel: + 81 3 5229 6900
Fax: + 81 3 5229 6903
info.japan@galderma.com
www.galderma.jp
MEXICO
Galderma Mexico SA de CV
José María Ibarrarán No. 20
Col. San José Insurgentes
Delegación Benito Juárez
C.P. 03900 México, D.F.
Tel: + 52 55 5593 43 53
Fax: + 52 55 5593 34 20
info.mexico@galderma.com
www.galderma.com.mx
PHILIPPINES
Galderma Philippines Inc.
Unit 3001 Atlanta Center
31 Annapolis Street
Greenhills, San Juan
Metro Manila ,1502
Tel: + 63 2 4708000
Fax: + 63 2 7440460
info.ph@galderma.com
POLAND
Galderma Polska Sp. Z.o.o.
ul. Laczyny 4
02-820 Warsaw
Tel: + 48 22 33 12 180
Fax: + 48 22 33 10 541
info.poland@galderma.com
www.galderma.pl
PORTUGAL
Galderma International SAS
Sucursal em Portugal
R. Dr. António Loureiro Borges
n°7- 6° Andar
Arquiparque-Miraflores
1495-131 Alges
Tel: + 351 21 315 19 40/41
Fax: + 351 21 315 27 18
galderma.portugal@galderma.com
RUSSIA
Galderma LLC
Moscow Representative Office
Stromynskiy Pereulok, 6
107076 Moscow
Tel: + 7 499269 15 96
Fax: + 7 499 269 15 97
info.russia@galderma.com
www.galderma.ru
SINGAPORE
Galderma Singapore Private Ltd.
1 Kim Seng Promenade
#10-11, Great World City
West Tower
Singapore 237994
Tel: + 65 6838 9360
Fax: + 65 6836 3312
info.sg@galderma.com
SOUTH AFRICA
Galderma Laboratories South
Africa (Pty) Ltd.
Wedgefield Office Park -
17 Muswell Road South Bryanston
Phase 2, Block D
1 ST Floor
PO Box 71150
Bryanston 2021
Tel: + 27 11 706 23 39
Fax: + 27 11 463 43 71
info.sa@galderma.com
SOUTH KOREA
Galderma Korea Ltd.
Bando Building 48-1
Banpo-dong, Seocho-Ku
Seoul 137-040
Tel: + 82 2 67 17 2000
Fax: + 82 2 67 17 2001
info.kr@galderma.com
www.galdermakorea.com
SPAIN
Laboratorios Galderma SA
C/ Agustín de Foxá, 29 - 6 PL.
28036 Madrid
Tel: + 34 902 02 7595
Fax: + 34 902 02 7578
info.spain@galderma.com
SWEDEN
Galderma Nordic AB
Gustavslundsvägen 151 C
PO Box 15028
S-167 51 Bromma
Tel: + 46 8 564 355 40
Fax: + 46 8 564 355 49
info.nordic@galderma.com
www.galderma.se
SWITZERLAND
Galderma SA
Avenue Gratta-Paille 2
1018 Lausanne
Tel: +41 21 642 78 00
Fax: +41 21 642 78 01
info.ch@galderma.com
TAIWAN
Galderma Hong Kong Ltd
Taiwan Branch
4-6, 9F, No. 17, Sec. 1
Chengde Road, Datong Dist.
Taipei City 103
Taiwan, R.O.C
Tel: + 886 2 2555 8850
Fax: + 886 2 2555 0850
info.tw@galderma.com
www.galderma.com.tw
19
THE NETHERLANDS
Galderma Netherlands
Branch Office
of Galderma SA
Avelingen-West, 3
4202 MS Gorinchem
Tel: + 31 1836 91 919
Fax: + 31 1836 91 918
info.nl@galderma.com
www.galderma.nl
UNITED KINGDOM
Galderma (UK) Ltd.
Meridien House, 3rd Floor
69-71 Clarendon Road
Watford, Hertfordshire
WD17 1DS
Tel: + 44 1 923 20 89 50
Fax: + 44 1 923 20 89 99
info.uk@galderma.com
www.galderma.co.uk
UNITED-STATES
Galderma Laboratories, LP
14501 North Freeway
Fort Worth, Texas 76177
Tel: + 1 817 961 5000
Fax: + 1 817 961 0035
productquestion@galderma.com
www.galdermausa.com
VENEZUELA
Laboratorios Galderma
Venezuela SA
Av. Lima con Paseo Colon
Torre Polar Este (Nestlé)
Piso 14, Oficina 14 A
Urb.Los Caobos Caracas
DC ZP 1050
Tel: + 58 212 708 8377
Fax: + 58 212 578 0646
info.venezuela@galderma.com
www.galderma.com.ve

Passionate.
Progressive.
A dermatology company
like no other.
Innovative medical solutions that meet
the needs of dermatology patients and
physicians.
Premier investor in dermatology research
State-of-the-art global research and development
Focus on therapeutic, corrective and aesthetic
innovations
Photos : Galderma, Stock Image, Stock Market, Istockphoto, Getty Images, Corbis - Copyrights Howard Schatz, L. Monneret - All mentioned brands belong to Galderma July 2010